Merus N.V. (MRUS)
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands.
Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.
The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma.
In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145.
The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
|IPO Date||May 19, 2016|
|CEO||Dr. Sven Ante Lundberg M.D.|
3584 Cm Utrecht, P7 3584 CM
|Phone||31 030 253 8800|
|Fiscal Year||January - December|
|Dr. Sven Ante Lundberg M.D.||Chief Executive Officer, President, Principal Financial Officer and Executive Director|
|Peter B. Silverman J.D.||Executive Vice President, General Counsel, Chief Intellectual Property Officer and Head of Utrecht and US Legal|
|Hui Liu Ph.D.||Chief Business Officer, Executive Vice President and Head of Merus U.S.|
|Dr. Hennie Hoogenboom||Co-Founder and Scientific Advisor|
|Harry Shuman||Chief Accounting Officer|
|Cornelis Adriaan de Kruif Ph.D.||Chief Technology Officer and Executive Vice President|
|Dr. Cecilia Anna Wilhelmina Geuijen Ph.D.||Chief Scientific Officer and Senior Vice President|
|Jillian Connell||Vice President of Investor Relations and Corporate Communications|
|Alexander Berthold Hendrik Bakker Ph.D.||Chief Development Officer and Executive Vice President|
|Dr. Andrew Joe M.D.||Chief Medical Officer and Senior Vice President|
Latest SEC Filings
|Jun 1, 2023||144||Filing|
|May 30, 2023||8-K||Current Report|
|May 23, 2023||8-K||Current Report|
|May 4, 2023||10-Q||Quarterly Report|
|Apr 28, 2023||DEF 14A||Other definitive proxy statements|
|Apr 18, 2023||PRE 14A||Other preliminary proxy statements|
|Apr 17, 2023||8-K||Current Report|
|Mar 10, 2023||SC 13G/A||[Amend] Statement of acquisition of beneficial ownership by individuals|
|Feb 28, 2023||RW||Filing|
|Feb 28, 2023||10-K||Annual Report|